Under construction – not a live service
Sign in
Taking people in GermanyNo phase

Tests cold water hydrotherapy added to rehabilitation after COVID-19

Tests cold water hydrotherapy with standard rehabilitation in adults with Post-COVID Syndrome.

Plain-language title generated from the registry record
Registry title: Effects of Hydrotherapy During Post-COVID-19 Rehabilitation

Key facts

Where
Schönau am Königssee, GermanySee the site

Where in Germany

  • Schön Klinik Berchtesgadener LandSchönau am Königssee, GermanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Schön Klinik Berchtesgadener Land
Trial code
NCT07013903
Record updated
28 August 2025
Original description
This randomized controlled study evaluates the effects of cold water hydrotherapy as an adjunct to standard rehabilitation in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to standard rehabilitation alone.Read full original descriptionShow less

Effects of Kneipp Hydrotherapy During Inpatient Post-Covid-19 Rehabilitation: A Randomized Controlled Trial

This randomized controlled study evaluates the effects of cold water hydrotherapy as an adjunct to standard rehabilitation in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to standard rehabilitation alone.

Inclusion: Diagnosis of Post-COVID Syndrome (ICD-10 code: U08.9); Barthel-Index >80; Referred to the reference center for Post-COVID rehabilitation; Owning a smartphone to receive digital questionnaires and to use the measurement app for heart rate variability; Written informed consent.

Exclusion: Prior regular practice of Kneipp applications; Existing contraindications for Kneipp hydrotherapy like severe cardiovascular diseases (e.g., decompensated heart failure, unstable angina pectoris, acute myocardial infarction), severe venous diseases (e.g., acute deep vein thrombosis of the leg), severe neurological diseases (e.g., uncontrolled epilepsy).

ClinicalTrials.gov NCT07013903